Treatment Used for Acute Lymphoblastic Leukemia Expanded to Patients with Minimal Residual Disease
According to a story from the biotechnology company Amgen, a review from the European Medicines Agency (EMA) has recommended that the indication for blinatumomab, marketed as BLINCYTO®, be expanded. The…